

LONDON (Alliance News) - Motif Bio PLC on Thursday said iclaprim delivered further positive results as part of its REVIVE-2 phase three trial.Motif Bi...


LONDON (Alliance News) - Motif Bio PLC's shares fell on Tuesday as the biopharmaceutical company said it has pushed back the date for its new drug app...


LONDON (Alliance News) - Motif Bio PLC said Wednesday it has raised GBP57,499 through the issue of 178,571 shares at a price of 32.2 pence per of


(ShareCast News) - As it prepares to list on the Nasdaq, AIM-listed antibiotics developer Motif Bio said it was likely to need extra funding as enrolm...